Avecho Biotechnology Limited

ASX:AVE Stock Report

Mkt Cap: AU$13.0m

Avecho Biotechnology Past Performance

Past criteria checks 0/6

Avecho Biotechnology has been growing earnings at an average annual rate of 18.2%, while the Pharmaceuticals industry saw earnings growing at 22.5% annually. Revenues have been declining at an average rate of 20.2% per year.

Key information

18.2%

Earnings growth rate

27.0%

EPS growth rate

Pharmaceuticals Industry Growth22.5%
Revenue growth rate-20.2%
Return on equity-96.6%
Net Margin-207.4%
Last Earnings Update31 Dec 2022

Recent past performance updates

Recent updates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

May 31
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Nov 04
Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Jul 14
We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Mar 23
We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Dec 08
We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Earnings and Revenue History

Quality Earnings: AVE is currently unprofitable.

Growing Profit Margin: AVE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVE is unprofitable, but has reduced losses over the past 5 years at a rate of 18.2% per year.

Accelerating Growth: Unable to compare AVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.3%).


Return on Equity

High ROE: AVE has a negative Return on Equity (-96.6%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies